GlassScriptPhysician profile
Vaishali V Saste
NPI 1902950033
$15,412.59
in general payments reported to CMS, 2019-2025
9 companies · $550 in 2025
The $550 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $1,900 · 2021: $11K · 2022: $700 · 2023: $200 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $550 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $550.00 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,490.00 | 2020-2021 | |
| Incyte Corporation | $4,980.35 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $1,050.00 | 2019 | |
| Cardinal Health 110 LLC | $550.00 | 2025 | |
| Daiichi Sankyo INC. | $200.00 | 2023 | |
| Gilead Sciences, INC. | $60.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.52 | 2019 | |
| Kite Pharma, INC. | $18.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaishali Saste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.